Coulter Partners Recruits CEO for BOOST Pharma
February 25, 2026 – Life sciences recruiting specialist Coulter Partners has recruited seasoned biotech entrepreneur Hans T. Schambye as the new CEO of BOOST Pharma in Stockholm, Sweden. “Hans joined BOOST Pharma at a pivotal time for the company,” said Ingelise Saunders, chair of BOOST Pharma. “Having already made an impact as a member of our board with his deep scientific insight and seasoned operational leadership, we are excited for him to step into the CEO role; he is the ideal fit to lead BOOST through its next phase of development.
“We are grateful to Coulter Partners for their work in identifying a leader of Hans’ caliber,” Ms. Saunders said. “Their ability to source high-level talent provided us with a natural and high-impact leadership solution as we advance our lead cell-therapy candidate.”
Dr. Schambye is a highly regarded biotech entrepreneur and operator with a proven record in building and leading companies from drug discovery to late-stage clinical development and pivotal value-creating milestones. He has extensive expertise in operational leadership, clinical program management, company growth, and financing and investor strategy. Dr. Schambye joins BOOST Pharma from Galecto Inc., where he served as president and CEO, leading the company through significant scientific, clinical, and financial milestones, and raising more than $500 million. He currently sits on the board of directors with BOOST Pharma.
Dr. Schambye also currently serves as chairperson of DANISH BIO and PreTT ApS and holds director positions at both BII and Tribune Therapeutics. His previous leadership roles include serving as CEO at ReceptIcon and Gastrotech Pharma A/S, as well as holding senior scientific and portfolio management positions at Maxygen in the United States. Dr. Schambye also co-founded ProFound Pharma A/S, which was acquired by Maxygen, Inc.
BOOST Pharma is a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases. This leadership transition occurs at a strategically important time for BOOST Pharma, as it advances BT‑101, its lead cell‑therapy candidate for osteogenesis imperfecta (OI), a rare genetic disorder also known as Brittle Bone Disease.
“BOOST Pharma brings together world‑class science, a truly exceptional team, and a late‑stage candidate with the potential to transform the lives of children with osteogenesis imperfecta,” said Dr. Schambye. “The strength of the BT‑101 data to date, combined with its path toward Phase III, is incredibly compelling. I am deeply motivated by what this company has already achieved and excited to help accelerate clinical development to address a clear unmet need.”
Serving Life Sciences Organizations
Coulter Partners is a board- and senior-level global executive search specialist focused exclusively on life sciences. The firm works closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, Coulter Partners is a trusted leadership adviser in the pharmaceuticals, biotechnology, medical technology, diagnostics, health-tech, CRO, and services sectors.
Related: Coulter Partners Recruits CFO for iOnctura
Coulter Partners also works closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. Coulter Partners’ team of 95 completes over 260 assignments a year working from 14 offices across the U.K., EMEA, the U.S., and APAC.
Bianca Coulter founded Coulter Partners in 2003 and has 25 years’ experience of board and C-level global search, building the leadership teams of early-stage, mid-cap, and global multinationals in over 20 countries. Through appointing leadership, Ms. Coulter channels her judgment and expertise to impact patient benefit and assist those at the cutting edge of life science to achieve their goals.
Trevi Therapeutics Search
Coulter Partners also recently placed David Hastings as the new CFO of NASDAQ-traded Trevi Therapeutics, Inc. in New Haven, CT. “I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi,” said Jennifer Good, president and CEO of Trevi Therapeutics. “His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough.”
“Filling this critical role required a search partner that could balance a thorough, robust process with a real sense of urgency, and Coulter Partners delivered on both counts,” Ms. Good added. “From the very beginning, the Coulter team demonstrated a deep understanding of our specific requirements and the Trevi culture. They worked in close partnership with us, leveraging their extensive network and assessment expertise to provide invaluable insights on prospective candidates. Ultimately, we relied on their trusted advice to identify the right fit for our team, and we are thrilled to welcome a leader of Dave’s caliber to Trevi.”
Related: Coulter Partners Recruits CFO for Tristel
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
